5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond

    July 2006 in “ European Urology Supplements ”
    Gerald L. Andriole
    Studysummary 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. A Randomized Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Finasteride for Male Chronic Pelvic Pain Syndrome (Category IIIA Chronic Nonbacterial Prostatitis) PubMed · 2004
    2. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998

    Related research 6

    1. Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair Clinica Chimica Acta · 2023
    2. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    3. Dutasteride in Androgenetic Alopecia: An Update Current Clinical Pharmacology · 2017
    4. Dutasteride for Men with Androgenic Alopecia Unresponsive to Finasteride Journal of Investigative Dermatology · 2016
    5. Atypical Post-Finasteride Syndrome: A Pharmacological Riddle Indian Journal of Pharmacology · 2016
    6. The Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice The FASEB Journal · 2013